Clinical Trials

596 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03520686 2026-04-15

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Terminated

102 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05635708 2026-04-15

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06151574 2026-04-15

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

416 enrolled

Lung Neoplasms

NCT06712316 2026-04-15

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

1,260 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06741644 2026-04-15

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

660 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06946797 2026-04-15

CheckMate-1533

76 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07005102 2026-04-15

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

854 enrolled

Neoplasms

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

68 enrolled

Gynecologic

Ovarian Neoplasms

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Phase 1 Recruiting

681 enrolled

Neoplasm Metastasis, Neoplasms

NCT06623422 2026-04-14

INTerpath-009

680 enrolled

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02609776 2026-04-13

CHRYSALIS

751 enrolled 2 FDA

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04077463 2026-04-13

Chrysalis-2

701 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-04-13

PAPILLON

308 enrolled 12 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT04686305 2026-04-13

DL03

Phase 1 Recruiting

304 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-04-13

PALOMA-2

520 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06312137 2026-04-13

TroFuse-019

780 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06333951 2026-04-13

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Phase 1 Recruiting

500 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06448754 2026-04-13

eVOLVE-01

180 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06459180 2026-04-13

TroFuse-020

686 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06793215 2026-04-13

Krascendo 2

600 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07190248 2026-04-13

KANDLELIT-007

675 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07252739 2026-04-13

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Phase 3 Not yet recruiting

130 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

494 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04083599 2026-04-08

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

350 enrolled

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT05083481 2026-04-08

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Phase 1/2 Active not recruiting

226 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06624059 2026-04-08

HORIZON 2

Phase 1/2 Active not recruiting

11 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07415031 2026-04-08

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

170 enrolled

Other solid neoplasm

Solid Tumors

NCT06875310 2026-04-07

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

630 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07063745 2026-04-07

MountainTAP-29

590 enrolled

Lung Neoplasms

NCT07128199 2026-04-07

REZILIENT4

360 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05112965 2026-04-06

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

49 enrolled

Neoplasms

NCT05261399 2026-04-06

SAFFRON

345 enrolled

Carcinoma, Neoplasm Metastasis

NCT07418749 2026-04-06

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

398 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05048797 2026-04-03

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

454 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07020221 2026-04-03

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

295 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04665206 2026-04-02

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Other solid neoplasmThoracic

434 enrolled

Mesothelioma

NCT06097728 2026-04-02

eVOLVE-Meso

Other solid neoplasmThoracic

825 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT06305754 2026-04-02

MK-2870-009

520 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03899155 2026-04-01

Pan Tumor Rollover Study

1,500 enrolled

Neoplasms

NCT04205812 2026-03-31

POD1UM-304

583 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06452277 2026-03-31

SOHO-02

444 enrolled

Advanced Non-small Cell Lung Cancer

NCT06561386 2026-03-31

RELATIVITY1093

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06788912 2026-03-31

MK-3475-01E

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT04129502 2026-03-30

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

354 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

210 enrolled

DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT04736173 2026-03-30

ARC-10

Phase 2 Active not recruiting

169 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06008093 2026-03-30

TRITON

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06996782 2026-03-30

ALTAIR

152 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07397338 2026-03-30

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors